share_log
Breakings ·  Dec 17 21:30
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (Sacituzumab Govitecan-Hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment